Table 4 Patients’ presentation and reported outcomes at baseline by treatment strategy, N (%)
|  | Wait and See (n = 81) | Surgery only (n = 41) | Systemic only (n = 37) |
|---|---|---|---|
Mean age [years] ± SD | 44.3 ± 15.17 | 41.8 ± 14.94 | 47.7 ± 10.44 |
Time since diagnosis primary tumor [months] median (Q1, Q3) | 34.3 (13.8–77.9) | 6.7 (1.2–59.8) | 32.1 (18.2–89.6) |
Treatment before baseline | Â | Â | Â |
 Therapy-naïve | 11 (13.6) | 16 (39.0) | – |
 Surgery only | 47 (58.0) | 20 (48.8) | 7 (18.9) |
 Systemic only | 2 (2.5) | – | 9 (24.3) |
 Multimodal treatment | 21 (25.9) | 5 (12.2) | 21 (56.8) |
Admission status | Â | Â | Â |
 Primary diagnosis | 47 (58.0) | 27 (65.9) | 19 (51.4) |
 Recurrent diseases | 34 (42.0) | 14 (34.1) | 18 (48.6) |
Indication MRI closest to baseline | Â | Â | Â |
 Primary diagnosis | 7 (9.3) | 23 (57.5) | 4 (11.4) |
 Pre-surgery | 5 (6.7) | 8 (20.0) | 2 (5.7) |
 Regular postoperative follow-up | 43 (57.3) | 6 (15.0) | 7 (20.0) |
 Follow-up due to complaints | 15 (20.0) | 2 (5.0) | 13 (37.1) |
Severity | Â | Â | Â |
 Moderate | 34 (42.0) | 15 (36.6) | 12 (32.4) |
 Severe | 38 (46.9) | 20 (48.8) | 21 (56.8) |
 Not assessable | 9 (11.1) | 6 (14.6) | 4 (10.8) |
In last 24Â months prior to baseline | Â | Â | Â |
 Any rehabilitation | 17 (26.2) | 5 (13.2) | 4 (12.5) |
 Specialist visitsa,  Median (range) | 5.0 (1.0–70.0) | 3.0 (10–27.0) | 12 (2.0–65.0) |
 Physical therapy sessionsa,  Median (range) | 18.0 (4.0–200.0) | 11.0 (1.0–100.0) | 11.5 (3.0–90.0) |
Symptoms | Â | Â | Â |
 Pain | 56 (69.1) | 37 (90.2) | 32 (86.5) |
 Stiffness | 36 (44.4) | 27 (65.9) | 23 (62.2) |
 Swelling | 44 (54.3) | 34 (82.9) | 19 (51.4) |
 Limited range of motion | 39 (48.1) | 31 (75.6) | 30 (81.1) |
 ≥ 3 symptoms | 31 (38.3) | 28 (68.3) | 22 (59.5) |
Analgesics use | 8 (9.9) | 5 (12.2) | 9 (24.3) |
Worst stiffness NRS Mean ± SD (n = 144) | 3.4 ± 2.57 | 5.2 ± 3.14 | 5.3 ± 2.55 |
Worst pain NRS Mean ± SD (n = 81) | 5.0 ± 2.41 | 6.5 ± 2.27 | 5.8 ± 1.97 |
Pain severity score Median (Q1, Q3) (n = 147) | 2.25 (0.75–4.00) | 4.25 (1.50–6.25) | 4.25 (1.50–5.50) |
Pain interference score Median (Q1, Q3) (n = 146) | 1.57 (0.14–4.00) | 3.00 (1.14–5.57) | 3.00 (0.57–5.57) |
PROMIS-PF Median (Q1, Q3) (n = 142) | 44.43 (37.30–49.29) | 39.54 (34.95–44.42) | 39.98 (34.79–43.69) |
EQ-5D Index score Median (Q1, Q3) (n = 153) | 0.84 (0.67–0.89) | 0.80 (0.53–0.84) | 0.74 (0.48–0.84) |
EQ-5D VAS Median (Q1, Q3) (n = 154) | 79.0 (60.0–85.0) | 69.0 (60.0–80.0) | 70.0 (50.0–75.0) |